Literature DB >> 9563757

Bacillus Calmette-Guérin revaccination questionable with low tuberculosis incidence.

M M Tala-Heikkilä1, J E Tuominen, E O Tala.   

Abstract

Bacillus Calmette-Guerin (BCG) revaccination was discontinued in Finland in 1990. The objective of this study was to assess the impact of BCG revaccination of tuberculin-negative school-children in prevention of tuberculosis. The tuberculosis cases in 1990-1995 were calculated among age cohorts born 1979-1984 and no longer covered by the BCG revaccination program. Corresponding data were collected for comparison from the period of revaccination in 1980-1985 among age cohorts born in 1969-1974. The National Tuberculosis Register was reviewed in order to observe the tuberculosis trend since 1980 in the age groups of 10-14 and 15-19 yr. Three cases of tuberculosis have been registered among non-BCG-revaccinated children during 6 yr after discontinuation of the program, i.e., 2.23 cases (95% CI 0.72 to 6.90) per million person yr. The control group revealed five cases, 3.78 (95% CI 1.57 to 9.07) per million person yr. The relative risk of tuberculosis in non-BCG-revaccinated children is 0.59 (95% CI 0.14 to 2.47) compared with the control group. The incidence of tuberculosis has continued to decline among adolescents since 1980. The follow-up data confirm that the cessation of BCG revaccination program had no effect on the continuing overall decline of tuberculosis in Finland. The efficacy of BCG revaccination seems to be low or nonexistent in countries with low tuberculosis incidence.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9563757     DOI: 10.1164/ajrccm.157.4.9706037

Source DB:  PubMed          Journal:  Am J Respir Crit Care Med        ISSN: 1073-449X            Impact factor:   21.405


  8 in total

1.  Enhancing the protective efficacy of Mycobacterium bovis BCG vaccination against tuberculosis by boosting with the Mycobacterium tuberculosis major secretory protein.

Authors:  Marcus A Horwitz; Günter Harth; Barbara Jane Dillon; Sasa Maslesa-Galic
Journal:  Infect Immun       Date:  2005-08       Impact factor: 3.441

2.  BCG revaccination boosts adaptive polyfunctional Th1/Th17 and innate effectors in IGRA+ and IGRA- Indian adults.

Authors:  Srabanti Rakshit; Asma Ahmed; Vasista Adiga; Bharath K Sundararaj; Pravat Nalini Sahoo; John Kenneth; George D'Souza; Wesley Bonam; Christina Johnson; Kees Lmc Franken; Tom Hm Ottenhoff; Greg Finak; Raphael Gottardo; Kenneth D Stuart; Stephen C De Rosa; M Juliana McElrath; Annapurna Vyakarnam
Journal:  JCI Insight       Date:  2019-12-19

3.  Cellular immune responses induced in cattle by heterologous prime-boost vaccination using recombinant viruses and bacille Calmette-Guérin.

Authors:  H Martin Vordermeier; Shelley G Rhodes; Gillian Dean; Nilu Goonetilleke; Kris Huygen; Adrian V S Hill; R Glyn Hewinson; Sarah C Gilbert
Journal:  Immunology       Date:  2004-07       Impact factor: 7.397

4.  Revaccination of neonatal calves with Mycobacterium bovis BCG reduces the level of protection against bovine tuberculosis induced by a single vaccination.

Authors:  B M Buddle; D N Wedlock; N A Parlane; L A L Corner; G W De Lisle; M A Skinner
Journal:  Infect Immun       Date:  2003-11       Impact factor: 3.441

Review 5.  Current status of new tuberculosis vaccine in children.

Authors:  Yu Pang; Aihua Zhao; Chad Cohen; Wanli Kang; Jie Lu; Guozhi Wang; Yanlin Zhao; Suhua Zheng
Journal:  Hum Vaccin Immunother       Date:  2016-03-22       Impact factor: 3.452

6.  Prime-boost BCG vaccination with DNA vaccines based in β-defensin-2 and mycobacterial antigens ESAT6 or Ag85B improve protection in a tuberculosis experimental model.

Authors:  Alberto R Cervantes-Villagrana; Rogelio Hernández-Pando; Arya Biragyn; Julio Castañeda-Delgado; Monica Bodogai; Margarita Martínez-Fierro; Eduardo Sada; Valentin Trujillo; Antonio Enciso-Moreno; Bruno Rivas-Santiago
Journal:  Vaccine       Date:  2012-11-26       Impact factor: 3.641

7.  Boosting of cellular immunity against Mycobacterium tuberculosis and modulation of skin cytokine responses in healthy human volunteers by Mycobacterium bovis BCG substrain Moreau Rio de Janeiro oral vaccine.

Authors:  Catherine A Cosgrove; Luiz R R Castello-Branco; Tracy Hussell; Amy Sexton; Rafaela Giemza; Richard Phillips; Andrew Williams; George E Griffin; Gordon Dougan; David J M Lewis
Journal:  Infect Immun       Date:  2006-04       Impact factor: 3.441

8.  Tuberculin skin test distribution following a change in BCG vaccination policy.

Authors:  Sei Won Lee; Soo Yeon Oh; Jin Beom Lee; Chang Min Choi; Hee Jin Kim
Journal:  PLoS One       Date:  2014-01-23       Impact factor: 3.240

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.